

CCR MANUSCRIPT NOTIFICATION (MARCH 2012)

Laboratory of Immune Cell Biology - Jonathan Ashwell, M.D.

There were no submissions reported this month.

Vaccine Branch - Jay Berzofsky, M.D., Ph.D.

There were no submissions reported this month.

CCR Nanobiology Program - Robert Blumenthal, Ph.D.

Belanger JM, Raviv Y, Viard M, Baxa U, and **Blumenthal R**: Orthogonal inactivation of influenza and the creation of detergent resistant viral aggregates: Towards a novel vaccine strategy. *Virology*. In press. (CCRNP)

Gong R, Chen W, and **Dimitrov DS**: Design, expression, purification and characterization of engineered antibody CH2 and VH domains. *Meth. Mol. Biol.* In press. (CCRNP)

Zhao Q, Zhu Z, and **Dimitrov DS**: Yeast display of engineered antibody domains. *Meth. Mol. Biol.* In press. (CCRNP)

Laboratory of Population Genetics - Kenneth Buetow, Ph.D.

There were no submissions reported this month.

Structural Biophysics Laboratory - R. Andrew Byrd, Ph.D.

There were no submissions reported this month.

Radiation Oncology Branch - Kevin Camphausen, M.D.

Gordon IK, Graves C, Kil WJ, Meushaw T, **Tofilon P**, and **Camphausen K**: Radiosensitization by the novel DNA intercalating agent vosaroxin. *Radiat Oncol.* 7(1): 26, 2012. (ROB)

Kil WJ, **Tofilon PJ**, and **Camphausen K**: Post-radiation increase in VEGF enhances glioma cell motility in vitro. *Radiat Oncol.* 7: 25, 2012. (ROB)

Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, Lippman ME, Glatstein E, Swain SM, Danforth DN, and **Camphausen K**: Twenty-five year results of the national cancer institute randomized breast conservation trial. *Breast Cancer Res Treat.* 132(1): 197-203, 2012. (ROB)

Jamal M, Rath BH, Tsang PS, **Camphausen K**, and **Tofilon PJ**: The Brain Microenvironment Preferentially Enhances the Radioresistance of CD133 Glioblastoma Stem-like Cells. *Neoplasia*. 14(2): 150-158, 2012. (ROB)

Nwe K, Milenic DE, Ray GL, Kim YS, and **Brechbiel MW**: Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography. *Mol Pharm*. 9(3): 374-381, 2012. (ROB)

Yong KJ, Milenic DE, Baidoo KE, and **Brechbiel MW**: 212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease. *Mol Cancer Ther*. 11(3): 639-648, 2012. (ROB)

Hayman TJ, Williams ES, Jamal M, Shankavaram UT, **Camphausen K**, and **Tofilon PJ**: Translation initiation factor eIF4E is a target for tumor cell radiosensitization. *Cancer Res*. In press. (ROB)

Kramp TR and **Camphausen K**: Combination radiotherapy in an orthotopic mouse brain tumor model. *J Vis Exp*. 61: e3397, 2012. (ROB)

Shankavaram UT, Bredel M, Burgan WE, Carter D, **Tofilon P**, and **Camphausen K**: Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. *J Cell Mol Med*. 16(3): 545-554, 2012. (ROB)

Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran Jr WJ, Dignam J, Efstathiou JA, Fitzgerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, **Coleman CN**, and Purdy J: Redesigning Radiotherapy Quality Assurance: Opportunities to Develop an Efficient, Evidence-Based System to Support Clinical Trials-Report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. *Int J Radiat Oncol Biol Phys*. In press. (ROB)

Molecular Imaging Program - Peter Choyke, M.D.

Choyke PL: Science to practice: imaging of cellular microparticles--magic dust or just dirt? *Radiology*. 263(1): 1-2, 2012. (MIP)

Kosaka N, Bernardo M, Mitsunaga M, **Choyke PL**, and **Kobayashi H**: MR and optical imaging of early micrometastases in lymph nodes: triple labeling with nano-sized agents yielding distinct signals. *Contrast Media Mol Imaging*. 7(2): 247-253, 2012. (MIP)

Mitsunaga M, Nakajima T, Sano K, **Choyke PL**, and **Kobayashi H**: Near-infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate. *Bioconjug Chem*. 23(3): 604-609, 2012. (MIP)

Laboratory of Cancer Prevention - Nancy Colburn, Ph.D.

Kasaikina MV, **Hatfield DL**, and Gladshv VN: Understanding selenoprotein function and regulation through the use of rodent models. *Biochim Biophys Acta*. In press. (LCP)

Mariotti M, Ridge PG, Zhang Y, Lobanov AV, Pringle TH, Guigo R, **Hatfield DL**, and Gladshv VN: Composition and evolution of the vertebrate and mammalian selenoproteomes. *PLoS One*. In press. (LCP)

Briones V and **Muegge K**: The ghosts in the machine: DNA methylation and the mystery of differentiation. *Biochim Biophys Acta*. In press. (LCP)

Neuro-Oncology Branch - Howard Fine, M.D.

There were no submissions reported this month.

Medical Oncology Branch - Giuseppe Giaccone, M.D., Ph.D.

Driscoll JJ, Burris J, and **Annunziata CM**: Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy. *Am J Ther*. 19(2): 133-144, 2012. (MOB)

Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, **Fojo T**, and **Bates SE**: A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors. *Oncologist*. In press. (MOB)

Bates SE: Molecular diagnostics: are we there yet? *Clin Cancer Res*. 18(6): 1514, 2012. (MOB)

West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, **Dennis PA**, Otterson GA, and Salgia R: A novel classification of lung cancer into molecular subtypes. *PLoS One*. 7(2): e31906, 2012. (MOB)

Chau CH and **Figg WD**: Angiogenesis inhibitors increase tumor stem cells. *Cancer Biol Ther*. In press. (MOB)

Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, and **Figg WD**: Racial Disparities in the Association Between Variants on 8q24 and Prostate Cancer: A Systematic Review and Meta-Analysis. *Oncologist*. In press. (MOB)

Petrini P, French CA, Rajan A, Cameron MJ, **Jaffe ES**, Zucali PA, Xie J, Wang Y, and **Giaccone G**: NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors. *J Thorac Oncol.* 7(4): 744-750, 2012. (MOB)

Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, **Luo J**, and Liu ZG: Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. *Proc Natl Acad Sci USA.* In press. (MOB)

Laboratory of Metabolism - Frank Gonzalez, Ph.D.

Postnikov YV, Kurahashi T, Zhou M and **Bustin M**: The Nucleosome Binding Protein HMG1 Interacts with PCNA and Facilitates its Binding to Chromatin. *Mol Cell Biol.* In press. (LM)

Kugler JE, Deng T and **Bustin M**: The HMG1 family of chromatin-binding proteins: Dynamic modulators of epigenetic processes. *Biochim Biophys Acta.* In press. (LM)

Laboratory of Cell Biology - Michael Gottesman, M.D.

Choi W, Kolbe L, and **Hearing VJ**: Characterization of the bioactive motif of neuregulin-1 (NRG-1), a fibroblast-derived paracrine factor that regulates the constitutive color and the function of melanocytes in human skin. *Pigment Cell Melanoma Res.* In press. (LCB)

Gillet J-P, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, **Ambudkar SV**, Seiden MV, Rueda BR, and **Gottesman MM**: Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. *Clin Cancer Res.* In press. (LCB)

Jenkins LMM, Durell SR, Mazur SJ, and **Appella E**: p53 N-Terminal Phosphorylation: A Defining Layer of Complex Regulation. *Carcinogenesis.* In press. (LCB)

Kang JH, Chang YC, and **Maurizi MR**: 4-O-carboxymethyl ascochlorin causes ER stress and induced autophagy in human hepatocellular carcinoma cells. *J Biol Chem.* In press. (LBC)

Kornhauser A, Coelho SG, and **Hearing VJ**: Effects of cosmetic formulations containing hydroxy acids on sun-exposed skin. *Dermatol Res Practice.* In press. (LCB)

Miller SA, Coelho SG, Miller SW, Yamaguchi Y, **Hearing VJ**, and Beer JZ: A new paradigm for UV exposure: a universal schedule that is skin phototype-independent. *Photoimmunol Photomed.* In press. (LCB)

Rottenberg S, Vollebergh M, Bas de Hoon J, Schouten P, Kersbergen A, Zander S, Pajic M, Jaspers J, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet J-P, **Gottesman MM**, Gribnau J, Wessels L, Linn S, Jonkers J, and Borst P: Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. *Cancer Res.* In press. (LCB)

Venkatesh M and **Subramaniam S**: Chemoreceptor arrays. Roberts G (Ed.). In: *Encyclopedia of Biophysics.* Springer Publishing. In press. (LCB)

Experimental Transplantation and Immunology Branch - Ronald Gress, M.D.

There were no submissions reported this month.

Laboratory of Biochemistry and Molecular Biology – Shiv Grewal, Ph.D.

There were no submissions reported this month.

Laboratory of Receptor Biology and Gene Expression - Gordon Hager, Ph.D.

Lickwar CR, Mueller F, Hanlon SE, **McNally JG** and Lieb JD: A clutch for transcription factor function. *Nature.* In press. (LRBGE)

Laboratory of Human Carcinogenesis - Curtis Harris, M.D.

There were no submissions reported this month.

HIV Drug Resistance Program - Stephen Hughes, Ph.D.

HIV DRP Host Virus Interaction Branch - Stephen Hughes, Ph.D.

There were no submissions reported this month.

Retroviral Replication Laboratory - Stephen Hughes, Ph.D.

Chung S, Miller JT, Johnson BC, **Hughes SH**, and **Le Grice SFJ**: Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinyllogous urea inhibition of ribonuclease H activity. *J. Biol. Chem.* 287: 4066-4075, 2012. (RRL)

Cingöz O, Paprotka T, Delviks-Frankenberry KA, Wildt S, **Hu W-S**, **Pathak VK**, and Coffin JM: Characterization, mapping, and distribution of the two XMRV parental proviruses. *J. Virol.* 86: 328-338, 2012. (RRL)

Freed EO and Martin MA: HIVs and their replication. Knipe DM and Howley PM (Eds.). In: Fields Virology, 6th Ed., Lippincott, Williams, and Wilkins: Philadelphia. In press. (RRL)

Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu L, **Le Grice SFJ**, Engelman A, Fuchs JR, and Kvaratskhelia M: A multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J. Biol. Chem. In press. (RRL)

Sztuba-Solinska J and **Le Grice SFJ**: Probing retroviral and retrotransposon genome structures: The "SHAPE" of things to come. Mol. Biol. Int. In press. (RRL)

Cell and Cancer Biology Branch - Kathleen Kelly, Ph.D.

There were no submissions reported this month.

Urologic Oncology Branch - W. Marston Linehan, M.D.

Linehan WM: The Genetic Basis of Kidney Cancer: Implications for Management and Use of Targeted Therapeutic Approaches. European Urol. In press. (UOB)

Linehan WM: Genetic Basis of Kidney Cancer: Critical Opportunity for a Genomic Future. Genome Res. In press. (UOB)

Moore LE, Jaeger E, Nickerson ML, Brennan P, DeVries S, Roy R, Toro J, Li H, Karami S, Lenz P, Zaridze D, Janout V, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, **Linehan WM**, **Merino M**, Simko J, Pfeiffer R, Boffetta P, **Hewitt S**, Rothman N, Chow WH, and Waldman FM: Genomic Copy Number Alterations in Clear Cell Renal Carcinoma: Associations With Case Characteristics and Mechanisms of VHL Gene Inactivation. Nature Oncogenesis. In press. (UOB)

Schmidt LS, Srinivasan R, and **Linehan WM**: The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies. In: Renal Cell Carcinoma: Biology, Prognostic Factors and Therapeutic Targets. R. Figlin, K. Rathwell, and B. Rini (Eds.). Springer. In press. (UOB)

Weisbrod A, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, **Linehan WM**, Nilubol N, and **Kebebew E**: Association of Type-O Blood With Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Syndrome. Ann Surg Oncol. In press. (UOB)

Cecchi F, Rabe DC, and **Bottaro D**: Targeting the HGF/Met Signaling Pathway in Cancer Therapy. Expert Opin Therapeutic Target. In press. (UOB)

Hoang AN, Volkin D, Yerram NK, Vourganti S, Nix J, **Linehan WM**, Wood B, and Pinto PA: Image Guidance in the Focal Treatment of Prostate Cancer. Curr Opin Urol. In press. (UOB)

Linehan WM: The Genetic Basis of Kidney Cancer: Implications for Management and Use of Targeted Therapeutic Approaches. *Eur J Urol*. In press. (UOB)

Mena E, Turkbey B, Mani H, Adler S, Valera VA, Bernardo M, Shah V, Pohida T, McKinney Y, Kwarteng G, Daar D, Lindenberg ML, Eclarinal P, Wade R, **Linehan WM**, **Merino MJ**, Pinto PA, **Choyke PL**, and Kurdziel KA: 11C-Acetate PET/CT in Localized Prostate Cancer: A Study With MRI and Histopathologic Correlation. *J Nucl Med*. In press. (UOB)

Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, **Linehan WM**, Pantuck AJ, Said JW, and Beldegrun AS: Impact of Pathological Tumour Characteristics in Patients With Sarcomatoid Renal Cell Carcinoma. *BJU Int*. In press. (UOB)

Shuch B, Bratslavsky G, **Linehan WM**, and Srinivasan R: Sarcomatoid Renal Cell Carcinoma: a Comprehensive Review of the Biology and Current Treatment Strategies. *The Oncologist*. 17(1): 46-54, 2012. (UOB)

Trivedi H, Turkbey B, Rastinehad AR, Benjamin CJ, Bernardo M, Pohida T, Shah V, **Merino MJ**, Wood BJ, **Linehan WM**, Venkatesan AM, **Choyke PL**, and Pinto PA: Use of Patient-Specific MRI-Based Prostate Mold for Validation of Multiparametric MRI in Localization of Prostate Cancer. *Urology*. 79(1): 233-239, 2012. (UOB)

Weisbrod AB, Kitano M, Gesuwan K, Millo C, Herscovitch P, Nilubol N, **Linehan WM**, and **Kebebew E**: Clinical Utility of Functional Imaging With 18F-FDOPA in Von Hippel-Lindau Syndrome. *J Clin Endocrinol Metab*. In press. (UOB)

Laboratory of Cellular Oncology - Douglas Lowy, M.D.

There were no submissions reported this month.

Pediatric Oncology Branch - Crystall Mackall, M.D.

There were no submissions reported this month.

Genetics Branch - Paul Meltzer, M.D., Ph.D.

Choy JS, Mishra PK, Au WC, and **Basrai MA**: Insights into assembly and regulation of centromeric chromatin in *Saccharomyces cerevisiae*. *Biochim Biophys Acta*. In press. (GB)

Hirsch D, Camps J, Varma S, Kemmerling R, Stapleton M, **Ried T**, and Gaiser T: A new whole genome amplification method for studying clonal evolution patterns in malignant colorectal polyps. *Genes Chromosomes Cancer*. 51(5): 490-500, 2012. (GB)

Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, **Ried T**, **Hassan R**, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, and Hussain SP: DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma. PLoS One. 7(2): e31507, 2012. (GB)

Ried T, Hu Y, Difilippantonio MJ, Ghadimi BM, Grade M, and Camps J: The consequences of chromosomal aneuploidy on the transcriptome of cancer cells. Biochim Biophys Acta. In press. (GB)

Ried T and Gaiser T: A recurrent fusion gene in high-grade endometrial stromal sarcoma: a new tool for diagnosis and therapy? Genome Med. 4(3): 20, 2012. (GB)

Lab of Cancer Biology & Genetics - Glenn Merlino, PhD and Stuart Yuspa, MD

There were no submissions reported this month.

Radiation Biology Branch - James Mitchell, Ph.D.

There were no submissions reported this month.

Laboratory of Cell and Developmental Signaling - Debbie Morrison, Ph.D.

There were no submissions reported this month.

Laboratory of Genomic Integrity – Andre Nussenzweig, Ph.D.

There were no submissions reported this month.

Laboratory of Pathology - J. Carl Oberholtzer, M.D., Ph.D.

There were no submissions reported this month.

Lab of Molecular Biology - Ira Pastan, M.D. and Susan Gottesman, Ph.D.

Pastan I and Zhang Y: Modulating mesothelin shedding to improve therapy. Oncotarget. 3: 114-115, 2012. (LMB)

Kelly RJ, Sharon E, **Pastan I**, and **Hassan R**: Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer Ther. 11: 517-525, 2012. (LMB)

Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, and **Cheng SY**: SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. *Clin. Cancer Res.* 18: 1281-1290, 2012. (LMB)

Cordas EA, Ng L, Hernandez A, Kaneshige M, **Cheng SY**, and Forrest D: Thyroid hormone receptors control developmental maturation of the middle ear and the size of the ossicular bones. *Endocrinology.* 153: 1548-1560, 2012. (LMB)

Cancer and Developmental Biology Laboratory - Alan Perantoni, Ph.D.

There were no submissions reported this month.

Laboratory of Molecular Pharmacology - Yves Pommier, M.D., Ph.D.

Morgan Jr RJ, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz HJ, and **Doroshov J**: Phase II trial of bryostatatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. *Invest. New Drugs.* 30: 723-728, 2012. (LMP)

Schilsky RL, **Doroshov JH**, Leblanc M, and Conley BA: Development and use of integral assays in clinical trials. *Clin. Cancer Res.* 18: 1540-1546, 2012. (LMP)

Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, and **Doroshov JH**: Advances in using PARP inhibitors to treat cancer. *BMC Med.* In press. (LMP)

Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RL, Parchment RE, Tomaszewski JE, and **Doroshov JH**: A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. *Clin. Cancer Res.* 18: 1726-1734, 2012. (LMP)

Doroshov JH, Juhasz A, Ge Y, Holbeck S, Lu J, Antony S, Wu Y, Jiang G, and Roy K: Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. *Biochem. Pharmacol.* 83: 1195-1207, 2012. (LMP)

Speranza G, Guiterrez ME, Kummar S, Strong JM, Parker RJ, Collins J, Yu Y, Cao L, Murgo AJ, **Doroshov JH**, and Chen A: Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. *Cancer Chemother. Pharmacol.* 69: 431-438, 2012. (LMP)

Solier S, Zhang YM, Ballestrero A, **Pommier Y**, and Zoppoli G: DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. *Curr. Cancer Drug Targets*. In press. (LMP)

Murai J, Huang SY, Das BB, Dexheimer TS, Takeda S, and **Pommier Y**: Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damages induced by topoisomerase I and II and base alkylation in vertebrate cells. *J. Biol. Chem.* In press. (LMP)

Doroshov JH: Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. *Curr. Pharm. Biotechnol.* In press. (LMP)

Surgery Branch - Steven Rosenberg, M.D., Ph.D.

There were no submissions reported this month.

Laboratory of Cellular and Molecular Biology - Larry Samelson, M.D.

There were no submissions reported this month.

Laboratory of Tumor Immunology and Biology - Jeffrey Schlom, Ph.D.

There were no submissions reported this month.

Experimental Immunology Branch - Alfred Singer, M.D.

There were no submissions reported this month.

Gene Regulation and Chromosome Biology Lab - Jeffrey Strathern, Ph.D.

There were no submissions reported this month.

Molecular Discovery Program – Jeffrey Strathern, Ph.D., Acting Program Director

Molecular Targets Laboratory - James McMahon, Ph.D.

There were no submissions reported this month.

Chemical Biology Laboratory - Joel Schneider, Ph.D.

Muthana SM, Campbell CT, and **Gildersleeve JC**: Modifications of glycans: Biological significance and therapeutic opportunities. *ACS Chem Biol.* 7: 31-43, 2012. (CBL)

Bahta M, Liu F, Kim SE, Stephen AG, Fisher RJ, and **Burke Jr TR**: Oxime-based linker libraries as a general approach for the rapid generation and screening of multidentate inhibitors. *Nature Protocols*. 7(4): 686-702, 2012. (CBL)

Geisler IM and **Schneider JP**: Evolution-based design of an injectable hydrogel. *Adv Funct Mater*. 22(3): 529-537, 2012. (CBL)

Laboratory of Experimental Carcinogenesis - Snorri Thorgeirsson, M.D., Ph.D.

Zhou X, Yang X-Y, and **Popescu NC**: Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells. *Biochem. Biophys. Res. Commun.* In press. (LEC)

Cancer and Inflammation Program - Giorgio Trinchieri, M.D.

Laboratory of Molecular Immunoregulation - Joost Oppenheim, M.D.

Yang D, Postnikov YV, Li Y, Tewary P, de la Rosa G, Wei F, **Klinman D**, Gioannini T, Weiss JP, Furusawa T, **Bustin M**, and **Oppenheim JJ**: High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. *J. Exp. Med.* 209: 157-171, 2012. (LMI)

Laboratory of Experimental Immunology - Giorgio Trinchieri, M.D.

Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, He W, Zeng L, Xing M, Wu R, Jiang H, Liu X, Cao D, Guo G, Hu X, Gui Y, Li Z, Xie W, Sun X, Shi M, Cai Z, Wang B, Zhong M, Li J, Lu Z, Gu N, Zhang X, Goodman L, Bolund L, Wang J, Yang H, Kristiansen K, **Dean M**, Li Y, and Wang J: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. *Cell*. 148: 886-895, 2012. (LEI)

Shirota Y, Shirota H, and **Klinman DM**: Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. *J. Immunol.* 188: 1592-1599, 2012. (LEI)

Whitson EL, Sun H, Thomas CL, Henrich CJ, **Sayers TJ**, **McMahon JB**, Griesinger C, and McKee TC: Synergistic TRAIL sensitizers from *Barleria alluaudii* and *Diospyros maritime*. *J. Nat. Prod.* 75: 394-399, 2012. (LEI)

Galon J, Pagès F, Marincola FM, Thurin M, **Trinchieri G**, Fox BA, Gajewski TF, and Ascierto PA: The immune score as a new possible approach for the classification of cancer. *J. Transl. Med.* 10: 1, 2012. (LEI)

Blackburn J, Ohazama A, Kawasaki K, Otsuka-Tanaka Y, Liu B, Honda K, Rountree RB, **Hu Y**, Kawasaki M, Birchmeier W, Schmidt-Ullrich R, Kinoshita A, Schutte BC, Hammond NL, Dixon MJ, and Sharpe PT: The role of Irf6 in tooth epithelial invagination. *Dev. Biol.* In press. (LEI)

Timofeeva OA, Chasovskikh S, Lonskaya I, Tarasova NI, Khavrutskii L, Tarasov SG, Zhang X, Korostyshevskiy VR, Cheema A, Zhang L, Dakshanamurthy S, Brown ML, and Dritschilo A: Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. *J. Biol. Chem.* 287: 14192-14200, 2012. (LEI; PI: **Trinchieri G**)

Berezhnoy A, Stewart CA, McNamara li JO, Thiel W, Giangrande P, **Trinchieri G**, and Gilboa E: Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. *Mol. Ther.* 20: 1242-1250, 2012. (LEI)

Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, and **Wiltrott RH**: Systemic IL-12 administration modulates dendritic cells to overcome immunosuppression inherent in the liver microenvironment. *Plos One.* 7: e33303, 2012. (LEI)

Stauffer JK, Scarzello AJ, Jiang Q, and **Wiltrott RH**: Chronic inflammation, immune escape and oncogenesis in the liver: a unique neighborhood for novel intersections. *Hepatology.* In press. (LEI)

Young H: Scientific Apps are here (and more will be coming). *Cytokine.* In press. (LEI)

Dermatology Branch - Mark Udey, M.D., Ph.D.

There were no submissions reported this month.

Mouse Cancer Genetics Program - Terry Van Dyke, Ph.D.

There were no submissions reported this month.

Metabolism Branch - Thomas Waldmann, M.D.

There were no submissions reported this month.

Laboratory of Protein Dynamics & Signaling - Allan Weissman, M.D.

There were no submissions reported this month.

Macromolecular Crystallography Laboratory - Alexander Wlodawer, Ph.D.

There were no submissions reported this month.

HIV and AIDS Malignancy Branch - Robert Yarchoan, M.D.

There were no submissions reported this month.

Basic Research Laboratory

There were no submissions reported this month.

Emeritus Scientists

Victor Marquez

Chen M, Shabashvilli D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, **Hunter KW**, Kaye FJ, Hochwald SN, **Marquez VE**, **Steeg P**, and Zajac-Kaye M: DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. *Mol Cancer Ther.* 11(2): 370-382, 2012. (CBL)

Diaz Perez SV, Kim R, Li Z, **Marquez VE**, Patel S, Plath K, and Clark AT: Derivation of new human embryonic stem cell lines reveals rapid epigenetic progression in vitro that can be prevented by chemical modification of chromatin. *Human Mol Gen.* 21(4): 751-764, 2012. (CBL)

He S, Wang J, Kato K, Xie F, Varambally S, Mineishi S, Kuick R, Mochizuki K, Liu Y, Nieves E, Mani R-S, Chinnaiyan AM, **Marquez VE**, and Zhang Y: Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. *Blood.* 119 (5): 1274-1282, 2012. (CBL)